India, July 21 -- Gilead Sciences, Inc. (GILD) and Merck (MRK), announced detailed results from the Phase 3 ISLEND-1 and ISLEND-2 trials evaluating the investigational once-weekly oral single-tablet regimen of Islatravir 2 mg/Lenacapavir 300 mg (ISL/LEN). The data, presented at the 26th International AIDS Conference, showed that ISL/LEN maintained high rates of virologic suppression at Week 48 in adults living with HIV, who switched from daily antiretroviral therapy.
Trial Results
In ISLEND-1, participants switching from BIKTARVY maintained virologic suppression, with no participants of ISL/LEN patients showing HIV-1 RNA = 50 copies/mL at Week 48 compared to 0.3% on BIKTARVY.
In ISLEND-2, patients switching from other standard daily regi...